What is Xeomin?
Xeomin is an injectable treatment derived from another type of botulinum toxin type A called incobotulinumtoxinA. Produced by the company Merz Pharmaceuticals, Xeomin was first approved for cosmetic use in 2010. When used for cosmetic purposes, the neurotoxin is best used to treat forehead lines (called glabellar lines), frown lines, and crow’s feet. Xeomin has also received FDA approval to treat excessive drooling among other conditions, such as blepharospasm and cervical dystonia. Xeomin is unique from other forms of the botulinum toxin A as it does not contain preservative proteins. This means that it is a pure form of the neurotoxin, which will not cause the body to produce antibodies. As a result, the body does not grow resistant to the treatment over time.